S&P 500   4,129.09 (-0.84%)
DOW   34,039.72 (-0.34%)
QQQ   305.53 (-1.40%)
AAPL   151.32 (-2.15%)
MSFT   268.74 (+0.44%)
META   185.16 (-3.37%)
GOOGL   99.08 (-7.95%)
AMZN   99.85 (-2.21%)
TSLA   198.62 (+0.92%)
NVDA   224.16 (+1.10%)
NIO   10.65 (-2.47%)
BABA   105.52 (+0.02%)
AMD   85.47 (-0.51%)
T   19.13 (-0.62%)
F   13.47 (+0.15%)
MU   60.60 (-2.46%)
CGC   2.76 (-2.13%)
GE   82.00 (-0.13%)
DIS   111.29 (-0.30%)
AMC   5.73 (-7.28%)
PFE   43.88 (+0.67%)
PYPL   80.16 (-3.69%)
NFLX   360.86 (-0.58%)
S&P 500   4,129.09 (-0.84%)
DOW   34,039.72 (-0.34%)
QQQ   305.53 (-1.40%)
AAPL   151.32 (-2.15%)
MSFT   268.74 (+0.44%)
META   185.16 (-3.37%)
GOOGL   99.08 (-7.95%)
AMZN   99.85 (-2.21%)
TSLA   198.62 (+0.92%)
NVDA   224.16 (+1.10%)
NIO   10.65 (-2.47%)
BABA   105.52 (+0.02%)
AMD   85.47 (-0.51%)
T   19.13 (-0.62%)
F   13.47 (+0.15%)
MU   60.60 (-2.46%)
CGC   2.76 (-2.13%)
GE   82.00 (-0.13%)
DIS   111.29 (-0.30%)
AMC   5.73 (-7.28%)
PFE   43.88 (+0.67%)
PYPL   80.16 (-3.69%)
NFLX   360.86 (-0.58%)
S&P 500   4,129.09 (-0.84%)
DOW   34,039.72 (-0.34%)
QQQ   305.53 (-1.40%)
AAPL   151.32 (-2.15%)
MSFT   268.74 (+0.44%)
META   185.16 (-3.37%)
GOOGL   99.08 (-7.95%)
AMZN   99.85 (-2.21%)
TSLA   198.62 (+0.92%)
NVDA   224.16 (+1.10%)
NIO   10.65 (-2.47%)
BABA   105.52 (+0.02%)
AMD   85.47 (-0.51%)
T   19.13 (-0.62%)
F   13.47 (+0.15%)
MU   60.60 (-2.46%)
CGC   2.76 (-2.13%)
GE   82.00 (-0.13%)
DIS   111.29 (-0.30%)
AMC   5.73 (-7.28%)
PFE   43.88 (+0.67%)
PYPL   80.16 (-3.69%)
NFLX   360.86 (-0.58%)
S&P 500   4,129.09 (-0.84%)
DOW   34,039.72 (-0.34%)
QQQ   305.53 (-1.40%)
AAPL   151.32 (-2.15%)
MSFT   268.74 (+0.44%)
META   185.16 (-3.37%)
GOOGL   99.08 (-7.95%)
AMZN   99.85 (-2.21%)
TSLA   198.62 (+0.92%)
NVDA   224.16 (+1.10%)
NIO   10.65 (-2.47%)
BABA   105.52 (+0.02%)
AMD   85.47 (-0.51%)
T   19.13 (-0.62%)
F   13.47 (+0.15%)
MU   60.60 (-2.46%)
CGC   2.76 (-2.13%)
GE   82.00 (-0.13%)
DIS   111.29 (-0.30%)
AMC   5.73 (-7.28%)
PFE   43.88 (+0.67%)
PYPL   80.16 (-3.69%)
NFLX   360.86 (-0.58%)
NASDAQ:DXCM

DexCom - DXCM Stock Forecast, Price & News

$109.92
+0.42 (+0.38%)
(As of 02/8/2023 12:50 PM ET)
Add
Compare
Today's Range
$108.74
$110.90
50-Day Range
$104.00
$122.67
52-Week Range
$66.89
$134.76
Volume
721,868 shs
Average Volume
2.48 million shs
Market Capitalization
$42.46 billion
P/E Ratio
202.62
Dividend Yield
N/A
Price Target
$121.94

DexCom MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
10.6% Upside
$121.94 Price Target
Short Interest
Bearish
3.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.37mentions of DexCom in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$12.56 M Sold Last Quarter
Proj. Earnings Growth
32.91%
From $0.79 to $1.05 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

243rd out of 1,029 stocks

Surgical & Medical Instruments Industry

22nd out of 105 stocks

DXCM stock logo

About DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Stock News Headlines

Insulet Has Potential To Gain More Than Analysts Are Forecasting (DXCM)
Even as it pulled back with the broader market Tuesday, insulin pump maker Insulet found support along its 50-day line and remained in possible buy range.
DexCom (DXCM) to Release Quarterly Earnings on Thursday
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 56,844 Shares
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Dexcom Appoints Teri Lawver as Chief Commercial Officer
DexCom: Tremendous Growth Prospects
DexCom (DXCM) Stock Moves -0.1%: What You Should Know
DexCom (DXCM) Stock Moves -0.94%: What You Should Know
Is This Stock-Split Stock a Buy For 2023?
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Company Calendar

Last Earnings
10/28/2021
Today
2/08/2023
Next Earnings (Confirmed)
2/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
7,000
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$121.94
High Stock Price Forecast
$146.00
Low Stock Price Forecast
$103.00
Forecasted Upside/Downside
+10.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$154.70 million
Pretax Margin
6.48%

Debt

Sales & Book Value

Annual Sales
$2.45 billion
Cash Flow
$0.98 per share
Book Value
$5.81 per share

Miscellaneous

Free Float
384,674,000
Market Cap
$42.46 billion
Optionable
Optionable
Beta
1.11

Social Links


Key Executives

  • Kevin Ronald Sayer
    Chairman, President & Chief Executive Officer
  • Jacob S. Leach
    Chief Operating Officer & Executive Vice President
  • Barry J. ReganBarry J. Regan
    Executive Vice President-Global Operations
  • Jereme M SylvainJereme M Sylvain
    Chief Financial Officer & EVP-Finance
  • Andrew K. BaloAndrew K. Balo
    EVP-Global Medical Affairs, Access & Evidence













DXCM Stock - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price forecast for 2023?

13 equities research analysts have issued 12-month price objectives for DexCom's stock. Their DXCM share price forecasts range from $103.00 to $146.00. On average, they predict the company's share price to reach $121.94 in the next twelve months. This suggests a possible upside of 11.5% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2023?

DexCom's stock was trading at $113.24 at the beginning of 2023. Since then, DXCM stock has decreased by 3.4% and is now trading at $109.34.
View the best growth stocks for 2023 here
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our DXCM earnings forecast
.

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, February 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) released its earnings results on Thursday, October, 28th. The medical device company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.07. The medical device company had revenue of $650.20 million for the quarter, compared to the consensus estimate of $617.07 million. DexCom had a trailing twelve-month return on equity of 13.27% and a net margin of 8.24%. The firm's revenue was up 29.8% on a year-over-year basis. During the same quarter last year, the company earned $0.24 EPS.
Read the conference call transcript
.

When did DexCom's stock split?

Shares of DexCom split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were distributed to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $815.00M-, compared to the consensus revenue estimate of $807.65 million.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.48%), Ownership Capital B.V. (0.51%), Fisher Asset Management LLC (0.36%), Allspring Global Investments Holdings LLC (0.35%), Sumitomo Mitsui Trust Holdings Inc. (0.29%) and Beacon Investment Advisory Services Inc. (0.19%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $109.34.

How much money does DexCom make?

DexCom (NASDAQ:DXCM) has a market capitalization of $42.23 billion and generates $2.45 billion in revenue each year. The medical device company earns $154.70 million in net income (profit) each year or $0.5425 on an earnings per share basis.

How many employees does DexCom have?

The company employs 7,000 workers across the globe.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.

This page (NASDAQ:DXCM) was last updated on 2/8/2023 by MarketBeat.com Staff